# Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

> **NCT02720601** · PHASE2 · WITHDRAWN · sponsor: **New Mexico Cancer Research Alliance**

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Irinotecan & Capecitabine

## Key facts

- **NCT ID:** NCT02720601
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11
- **Primary completion:** 2018-03
- **Final completion:** 2020-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never submitted to the IRB \& never opened. PI is leaving institution.
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02720601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02720601, "Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02720601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*